PDF(Pubmed)
Abstract：
Nirmatrelvir-ritonavir (Paxlovid) is a brand-new oral antiviral medication for treating mild to severe COVID-19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir-nirmatrelvir on December 22, 2021, to treat COVID-19. We describe a case of mild COVID-19 infection who developed severe hyponatremia following the administration of Paxlovid. Clinical and laboratory evaluations suggest SIADH, likely secondary to Paxlovid. The potential side effects of this medication still require further study.
摘要：
Nirmatrelvir-ritonavir（Paxlovid）是一种全新的口服抗病毒药物，用于治疗轻度至重度COVID-19。美国食品和药物管理局（FDA）于2021年12月22日发布了利托那韦-尼马特雷韦的紧急使用授权（EUA），用于治疗COVID-19。我们描述了一例轻度COVID-19感染病例，在服用Paxlovid后出现严重低钠血症。临床和实验室评估表明SIADH，可能继发于Paxlovid.这种药物的潜在副作用仍需进一步研究。
